Akebia Q2 revenue falls on lower Auryxia sales
AKBA•Vafseo growth offsets part of the weakness
Second-quarter net product revenue for Vafseo rose 60% year over year, with 41% more patients on therapy.
Akebia attributed the higher Vafseo revenue to increased patient uptake and more prescribers.
Quarterly revenue falls as Auryxia sales decline
Akebia said its U.S. kidney disease drugmaker's second-quarter revenue fell year over year on lower Auryxia sales.
The company said lower Auryxia revenues were due to generic competition and pricing pressure.
Losses beat expectations and company outlines outlook
Akebia's second-quarter net loss and loss per share both beat analyst expectations.
| Metric | Beat/Miss | Actual | Consensus Estimate |
|---|---|---|---|
| Q2 Loss Per Share | Beat | $0.03 | $0.04 (5 Analysts) |
| Q2 Net Loss | Beat | $8.91 mln | $11.17 mln (5 Analysts) |
| Q2 Operating Income | Slight Beat* | -$6.33 mln | -$6.38 mln (5 Analysts) |
| Q2 Loss Per Basic Share | $0.03 | ||
| Q2 Operating Expenses | $45.03 mln |
The company expects Auryxia revenues to decrease in 2026 due to generic competition and pricing pressure. Akebia expects initial data from its Phase 2 ebribafusp trial in 2027 and said current cash and expected revenues will fund operations for at least two years.
